Brief: Allakos Announces Expansion Of Lirentelimab Development Into Atopic Dermatitis, Chronic Spontaneous Urticaria And Asthma
30/11/2021 12:51
Nov 30 (Reuters) - Allakos Inc ALLK.O :
* ALLAKOS ANNOUNCES EXPANSION OF LIRENTELIMAB DEVELOPMENT
INTO
ATOPIC DERMATITIS, CHRONIC SPONTANEOUS URTICARIA AND ASTHMA
* ALLAKOS INC - PHASE 2 ATOPIC DERMATITIS TRIAL OF
SUBCUTANEOUS
LIRENTELIMAB INITIATED
* ALLAKOS INC - PHASE 2/3 CHRONIC SPONTANEOUS URTICARIA
TRIAL OF
SUBCUTANEOUS LIRENTELIMAB TO BEGIN IN MID 2022
* ALLAKOS INC - PHASE 2 ASTHMA TRIAL OF SUBCUTANEOUS
LIRENTELIMAB
TO BEGIN IN Q4 2022
Source text for Eikon: ID:nGNX7LtyQs
Further company coverage: ALLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences